RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

15/11/2016 - 2 minutes

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment?  

Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and chip in up to €93M ($100M) to take part in the co-development and co-commercialization of fitusiran, a treatment for hemophilia. Alnylam recently released positive data from a Phase I study and plans to initiate Phase III in early 2017.

The new data seems to have encouraged Sanofi, which will pay Alnylam up to €70M ($75M) in milestones and 20% in sale royalties. If successful, the deal could be very profitable: the hemophilia market is expected to reach €14.2B by 2024.

Sanofi RNAi

However, this could be a risky move for Sanofi; RNAi was hailed as a revolutionary approach for therapeutics when it won the Nobel Prize a decade ago.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member